Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Neovacs SA

www.neovacs.fr

Latest From Neovacs SA

Pipeline Watch: Phase III Progress With Tecentriq, Rolontis And ADV7103

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

 

Pipeline Watch Approvals

Neovacs CEO: 'We Need A Phase III Partner Now' To Progress Our Lupus Asset

French biotech says it has adequate Phase II data to design a pivotal study with regulators, but needs trial funding and a big pharma partner.

Business Strategies Clinical Trials

Deals Shaping The Medical Industry, March 2017

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in February 2017.

Deals BioPharmaceutical

Deal Watch: Otsuka’s Neurovance Buy Adds ADHD Candidate To CNS Pipeline

Otsuka's purchase of Neurovance is part of a larger strategy to replace revenues lost to patent expiration of Abilify. Meanwhile, its Japanese counterpart Takeda is overhauling its R&D engine with help from contract manufacturer Bushu.

Deals M & A
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
    • Vaccines
  • Therapeutic Areas
  • Cancer
  • Dermatology
  • Immune Disorders
  • Inflammation
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • France
  • Parent & Subsidiaries
  • Neovacs SA
  • Senior Management
  • Vincent Serra, CEO
    Therese Croughs, MD, CMO
  • Contact Info
  • Neovacs SA
    Phone: (33) 53 10 93 00
    3-5 Impasse Reille
    Paris, 75014
    France
Advertisement
Advertisement
UsernamePublicRestriction

Register